Aventis' Actonel Reaches 10% Of New Weekly Prescriptions For Osteoporosis
Executive Summary
Aventis' share of new prescriptions for its osteoporosis therapy Actonel is almost 10%, Investor Relations Director Arvind Sood said during a third quarter earnings call Nov. 9.